As Q2 numbers had already been pre-released, yesterday's report (12 August) did not contain any surp...
Redeye comments on Xspray’s out-licensing of certain patents covering the commercialization of a das...
The company’s adjusted EBITDA was EUR 3.1m (pre-announced) in Q2.
Redeye gives its preview on OssDsign’s Q2 2025 report, due on August 19.
Redeye provides an initial take on the Q2 2025 report from Scandinavian ChemoTech.
Q2 confirms that Moberg’s Terclara is now the market leader in both Sweden and Norway.
Raute’s EUR 43.8m Q2 top line came in clearly below our estimate, yet the EUR 6.
Endomines reports its H1 figures on 14th of August.
Market conditions remain unfavourable for Aurdel Septon divestment carries largest impact on estimat...
Q2 report due on Thursday, 14 August Sales and margin downgrades in Germany weigh on estimates Tradi...
Redeye comments on Alzinova’s announcement of having submitted an IND application and a Fast Track D...
Q2e sales of SEK 52m, 22% y-o-y, adj. EBIT of SEK 17m (12m) FX headwinds, but we expect customer gro...
Vi inleder bevakning på mResell, en ledande svensk aktör inom re-commerce som specialiserar sig på r...
SRV’s Q2 figures fell short of our estimates for both volumes and profitability.
Redeye comments on q.beyond’s Q2 report showing a slightly more substantial improvement in EBITDA an...
Redeye returns with a more in-depth take on the Q2 report.
Administer reports Q2 on August 14. We expect net sales and profitability to remain broadly flat y/y...
Redeye notes a soft Q2 on both sales and EBIT, and we expect a negative share price reaction today o...
CapMan’s operative performance in Q2 on comparable basis was decent, although the operating profit f...
SRV's net sales in Q2 amounted to EUR 168.7m, slightly below our estimate of EUR 174.
